Within PRIME-ROSE, Work Package 5 (EU Implementation in Everyday Practice) introduces a conceptual framework to evaluate targeted therapies in oncology from a health economic perspective. The team develops new tools and evidence to support national decision-makers in implementing precision cancer medicine in everyday healthcare systems.

🔎 In a new publication in Acta Oncologica, Oskar Frisell, Eline Aas and Katarina Steen Carlsson together with colleagues address key challenges in evaluating molecularly targeted therapies — and propose practical solutions.

The main contribution: a framework that enables consistent and flexible cost-effectiveness assessments of biomarker-driven, tumour-agnostic treatments by combining evidence across cancer types, while still allowing tumour-specific analyses when sufficient data are available.

👉Read more and download the publication: A conceptual health economic modelling framework to assess the cost-effectiveness of molecular target–driven treatment regimens in oncology.